Among treated patients at very high fracture risk, 21.2% received a pooled guideline-recommended medicine category that included abaloparatide.
In plain wordsAmong treated patients at very high fracture risk, 21.2% received a recommended medicine from a group that included abaloparatide.
- Peptide
- Abaloparatide (Tymlos)
- Outcome
- Not applicableGuideline-recommended medication use
- Study
n = 280,777
- Outcome group
- Patterns of use · Whole body
Measurements
- Recommended medicine use
- 21.2%
- treated patients
Source sentences
Of these, 63.6% received alendronate, an alternative therapy, and 21.2% received a risk-based guideline-recommended medicine (teriparatide, zoledronic acid, denosumab, abaloparatide, or romosozumab).
2 context sentences(design, population, supporting numbers)
Among the 1,667,794 patients (32.8%) eligible for treatment, 280,777 (16.8%) received treatment.
This retrospective observational cohort study used real-world data linked to commercial and Medicare medical claims from Symphony Health PatientSource.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).